Table 2.
NAT1 genotype frequency in AD cases and controls.
| NAT1 GENOTYPE | AD CASES (N = 147) | CONTROLS (N = 111) | EXPECTED | OR (95% CI) |
| 1*4/1*4 | 81 (0.55) | 65 (0.59) | 0.63 | 1.00 |
| 1*4/1*10 | 43 (0.29) | 33 (0.30) | 0.24 | 1.05 (0.60, 1.83) |
| 1*4/1*3 | 7 (0.05) | 7 (0.06) | 0.05 | 0.80 (0.27, 2.40) |
| 1*4/1*14A | 5 (0.03) | 4 (0.04) | 0.03 | 1.00 (0.26, 3.89) |
| 1*4/1*11A | 3 (0.02) | 2 (0.02) | 0.01 | 1.20 (0.20, 7.42) |
| 1*10/1*10 | 6 (0.04) | 0 (0) | 0.02 | - |
| 1*3/1*10 | 2 (0.01) | 0 (0) | 0.01 | - |
| Others | 0 (0) | 0 (0) | 0.01 | - |
| TOTAL | 147 (1.00) | 111 (1.00) | 1.00 | - |
The number and frequency (in brackets) of NAT1 genotypes in 147 AD cases and 111 controls is shown. Expected genotype frequency was calculated based on the allele frequency in the control group (Table 1). 'Others' includes additional NAT1 genotypes containing the alleles 1*4, 1*3, 1*10, 1*11A and 1*14A expected at low frequency which were not observed in these AD cases and controls. The OR of AD to non-disease is given with 95% CI for each NAT1 genotype (with NAT1*4/NAT1*4 as the reference group).